Novo Nordisk A/S
The purpose of this observational study is to measure how many people are overweight or obese amongst patients with a diagnosed cardiovascular disease (CVD). The study also aims to characterise the population including the presence of cardiovascular (CV) risk factors in a number of countries across the globe representing different geographies, ethnicities, as well as different healthcare systems.
Obesity
Overweight
No treatment given
Study Type : | OBSERVATIONAL |
Estimated Enrollment : | 5360 participants |
Official Title : | Multi-centre Cross-sectional Observational Study to Characterize the Prevalence of Overweight and Obesity Among Patients With Established Cardiovascular Disease |
Actual Study Start Date : | 2023-06-12 |
Estimated Primary Completion Date : | 2024-06-24 |
Estimated Study Completion Date : | 2024-06-24 |
Information not available for Arms and Intervention/treatment
Ages Eligible for Study: | 18 Years |
Sexes Eligible for Study: | ALL |
Want to participate in this study, select a site at your convenience, send yourself email to get contact details and prescreening steps.
Not yet recruiting
Novo Nordisk Investigational Site
Plainsboro, New Jersey, United States, 08536
Not yet recruiting
Novo Nordisk Investigational Site
São Paulo, Brazil,
Not yet recruiting
Novo Nordisk Investigational Site
Ontario, Canada,
Not yet recruiting
Novo Nordisk Investigational Site
Riyadh, Saudi Arabia,
Not yet recruiting
Novo Nordisk Investigational Site
Madrid, Spain,